Related Experiment Video
Updated: Feb 19, 2026
Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
Published on: July 13, 2019
Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic
Ivan Jelcic1, Benoit Combaluzier2, Ilijas Jelcic1
1Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University of Zurich, University Hospital Zurich, Switzerland.
Abstract:
Progressive multifocal leukoencephalopathy (PML) is a serious opportunistic infection of the brain caused by the JC polyomavirus (JCPyV). PML occurs when immune control of persistent infection with JCPyV fails, the virus mutates and changes its cellular tropism, enters the brain and infects astrocytes, oligodendrocytes and, in particular cases, also neurones. Currently, there is no therapy for this often fatal disease. A number of approaches have failed, and only the restoration of protective immunity, if possible, can lead to clearance of the virus once PML has occurred. During the last two decades, investigators have attempted to understand the factors contributing to the development of PML, which immune mechanisms are involved in immune surveillance, and which in clearing JCPyV from the brain once PML has occurred. Recent data suggest that both CD4+ and CD8+ T cells of the cellular immune system, and also JCPyV-specific antibodies, are involved in protection against PML and in resolving the opportunistic infection. Based on the current immunological data, prophylactic and therapeutic vaccination strategies have been proposed, and first treatment attempts in PML patients have provided promising results that indicate therapeutic vaccination may be feasible.
Insights
Progressive multifocal leukoencephalopathy (PML) is a severe brain infection caused by the JC polyomavirus (JCPyV). Restoring immune function and developing JCPyV-specific vaccines show promise for treating this often fatal condition.
Area of Science:
- Neuroimmunology
- Virology
- Infectious Diseases
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, fatal opportunistic infection of the brain.
- PML is caused by the JC polyomavirus (JCPyV) reactivating when immune defenses are compromised.
- Currently, no specific therapy exists for PML, with immune restoration being the primary management strategy.
Purpose of the Study:
- To investigate the immunological factors involved in PML development and JCPyV clearance.
- To explore the potential of prophylactic and therapeutic vaccination strategies for PML.
- To evaluate the feasibility of therapeutic vaccination in PML patients.
Main Methods:
- Review of recent immunological data concerning PML pathogenesis.
- Analysis of the roles of CD4+ and CD8+ T cells and JCPyV-specific antibodies in immune surveillance and viral clearance.
- Assessment of proposed vaccination strategies based on current immunological understanding.
Main Results:
- Both cellular immunity (CD4+ and CD8+ T cells) and humoral immunity (JCPyV-specific antibodies) are crucial for protection against PML and resolving JCPyV infection.
- Recent data indicate that therapeutic vaccination strategies are promising for PML treatment.
- Initial treatment attempts with vaccination in PML patients have yielded encouraging results.
Conclusions:
- Immune responses, particularly T cell and antibody-mediated immunity, play a critical role in controlling JCPyV and preventing/resolving PML.
- Therapeutic vaccination represents a feasible and promising strategy for managing PML.
- Further research and clinical trials are warranted to optimize vaccination approaches for PML patients.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
05:51Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Published on: July 24, 2016
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:26Pharmaceutical Poisoning: Treatment Strategies
01:14Myocarditis III: Medical Management
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...